We have assessed the dose-response relationship of a solution of ropivacaine 2 mg ml 91 , given as a continuous extradural infusion to women in labour. A total of 133 parturients were allocated randomly to one of four groups to receive a fixed rate ropivacaine infusion of 4, 6, 8 or 10 ml h 91 with additional bolus doses as necessary. Contraction pain, quality of analgesia, sensory block, motor block and neonatal Apgar scores were assessed. There were no significant differences between groups in terms of analgesia or motor block, although significantly more bolus doses were required by the group receiving 4 ml h 91 (P:0.05 compared with the other groups), and a significantly higher total dose of ropivacaine was administered to the 10-ml h 91 group compared with the 6-ml h 91 group (P:0.044). There were no significant differences between groups in terms of obstetric or neonatal outcome. We conclude that ropivacaine 2 mg ml 91 was effective and well tolerated when given as a continuous extradural infusion at 6-8 ml h 91 and may be used as the sole analgesic during labour. (Br.
Ropivacaine is a long-acting amide local anaesthetic and is the first enantiomerically pure anaesthetic of its type to be developed. It has been shown to have lower central nervous system and cardiovascular toxicity, and to produce slightly less motor block than equivalent doses of bupivacaine in surgical patients. 1 Several studies have compared ropivacaine 2.5 mg ml 91 with bupivacaine 2.5 mg ml 91 for analgesia in labour. [2] [3] [4] Although most factors were found to be affected similarly by each drug, ropivacaine was associated with a significantly lower incidence of instrumental delivery, 3 and higher neurological adaptive capacity scores (NACS) of the neonate, 2 and 24 h after delivery, 3 4 which in one case were significantly improved. 3 Furthermore, a volunteer study 5 
Methods and results
We studied 134 parturients in whom extradural analgesia was planned, and who were at least 18 yr of age, of less than 110 kg body weight, and pregnant with a singleton fetus (in the vertex position); they were allocated randomly to one of four groups to receive ropivacaine 2 mg ml 91 at fixed extradural infusion rates of 4, 6, 8 or 10 ml h 91 (8, 12, 16 or 20 mg h 91 ). The investigation, which was approved by the Ethics Committee of the co-ordinating centre, was explained fully to the patients (according to the Helsinki declaration) and written consent was obtained.
Exclusion criteria included: a history of allergy or sensitivity to amide local anaesthetics; administration of analgesics before the extradural; maternal medical conditions such as neurological disease, pre-eclampsia, drug abuse or psychiatric illness; and known fetal abnormalities.
The extradural procedure was started during labour. After local infiltration, a 16-18 gauge Tuohy needle was inserted in one of the L1-4 vertebral interspaces and the extradural catheter sited after intravascular or intrathecal placement had been excluded. An initial dose of ropivacaine 10 ml was delivered by fractional injection. The ropivacaine infusion was started within 15 min of the initial dose and was continued until delivery. Additional 5-ml bolus doses were allowed at the discretion of the investigator during the infusion period, providing the total dose did not exceed 450 mg, or 175 mg in any 3-h period. Administration of oxytocin was allowed at any time during the procedure and patients experiencing hypotension or bradycardia received ephedrine or volume loading, or both. If concurrent analgesics other than nitrous oxide were required before delivery, the patient was withdrawn from the study.
Onset of pain relief was assessed at each contraction using a four-point verbal scale. Contraction pain was assessed using a visual analogue scale (VAS), graded from 0 mm (no pain) to 100 mm (worst imaginable pain). Assessments were made for two consecutive contractions 5-10 min before commencing the extradural procedure, after the initial dosing, and thereafter at the first contraction after successive 30-min intervals. Spread of sensory block was assessed bilaterally every hour by pinprick. Overall quality of pain relief throughout labour was evaluated by the parturient immediately after delivery. Motor block was assessed bilaterally every hour using the modified Bromage scale, and other assessments made are listed in table 1. All adverse events for mother, fetus and neonate were recorded during labour, and at regular post-partum followups until 2-3 weeks after birth. No attempt was made to standardize obstetric management between centres as the primary goal of this study was to evaluate analgesia.
Data were analysed using Wilcoxon rank sum tests or chi-square tests, stratified for centre. P values were adjusted for multiple comparisons using the Bonferroni-Holm method and those values :0.05 were considered statistically significant.
The four groups were similar in patient characteristics and 54 women were multiparae. Of the 134 parturients, data from 133 who received ropivacaine were valid for analyses of efficacy and safety and are summarized in table 1.
Duration of treatment, was slightly, but not significantly, longer in the 10-ml h 91 group (median 4.63 h compared with 3.55-4. h). Total dose of ropivacaine administered, however, was significantly higher in the 10-ml h 91 group (median 127.6 mg) than in the 6-ml h 91 group (median 84.6 mg). Furthermore, the number of bolus doses administered per hour was significantly higher in the 4-ml h 91 group than in the other groups (P:0.025 (4 ml h 91 vs 6 ml h ). There were no significant differences between groups in any of the characteristics of analgesia and motor block scores immediately before transition to stage 2 of labour. The incidence of spontaneous head delivery was similar between groups (63-76%). Median Apgar scores of all neonates at 1 and 5 min after delivery were 9 and 10, respectively, with four newborns having scores of :7, 1 min after delivery. At 5 min after delivery, only two newborns had scores of :10 and both children registered scores of 9.
The incidence of adverse events was similar between groups. The most frequent adverse event in the mothers, fetuses and neonates was mild to moderate hypotension (19 of 133), deceleration (25 of 133) and temporary jaundice (36 of 133), respectively. 
